Thrombocytopenia-associated mutations in Ser/Thr kinase MASTL deregulate actin cytoskeleton dynamics in platelets by Hurtado Villarejo, Begoña et al.
Thrombocytopenia-associated mutations in
Ser/Thr kinase MASTL deregulate actin
cytoskeleton dynamics in platelets
Begoña Hurtado, … , Pablo García de Frutos, Marcos
Malumbres
J Clin Invest. 2018. https://doi.org/10.1172/JCI121876.
   
Graphical abstract
Research In-Press Preview Cell biology Hematology




Thrombocytopenia-associated mutations in Ser/Thr kinase 
MASTL deregulate actin cytoskeleton dynamics in platelets 
 
Begoña Hurtado,1,2* Marianna Trakala,1* Pilar Ximénez-Embún,3 Aicha El Bakkali,1 
David Partida,1 Belén Sanz-Castillo,1 Mónica Álvarez-Fernández,1 María Maroto,1 Ruth 
Sánchez-Martínez,1 Lola Martínez4, Javier Muñoz,3 Pablo García de Frutos2 and Marcos 
Malumbres1,ǂ  
* These authors contributed equally to this work. 
 
1 Cell Division and Cancer Group, Spanish National Cancer Research Centre (CNIO) 
Madrid, Spain 
2 Department of Cell Death and Proliferation, IIBB-CSIC, IDIBAPS, Barcelona, Spain 
3 ProteoRed-ISCIII and Proteomics Unit, CNIO, Madrid, Spain 
4 Cytometry Unit, CNIO, Madrid, Spain 
 
ǂ Correspondence: M. Malumbres. Centro Nacional de Investigaciones Oncológicas 
(CNIO), Melchor Fernández Almagro 3, E-28029 Madrid, Spain. Tel. +34 91 732 8000, 
Fax +34 91 732 8033; E-mail: malumbres@cnio.es 






MASTL, a Ser/Thr kinase that inhibits PP2A-B55 complexes during mitosis, is mutated 
in autosomal dominant thrombocytopenia. However, the connections between the cell 
cycle machinery and this human disease remain unexplored. We report here that, whereas 
Mastl ablation in megakaryocytes prevented proper maturation of these cells, mice 
carrying the thrombocytopenia-associated mutation developed thrombocytopenia as a 
consequence of aberrant activation and survival of platelets. Activation of mutant 
platelets was characterized by hyper-stabilized pseudopods mimicking the effect of PP2A 
inhibition and actin polymerization defects. These aberrations were accompanied by 
abnormal hyper-phosphorylation of multiple components of the actin cytoskeleton and 
were rescued both in vitro and in vivo by inhibiting upstream kinases such as PKA, PKC 
or AMPK. These data reveal an unexpected role of Mastl in actin cytoskeleton dynamics 
in postmitotic cells, and suggest that the thrombocytopenia-associated mutation in 
MASTL is a pathogenic dominant mutation that mimics decreased PP2A activity 




Mastl (Microtubule-Associated Serine/Threonine protein kinase-Like; also known as 
Greatwall) is a recently characterized kinase with critical functions in the maintenance of 
mitosis (1, 2). This kinase was originally discovered in Drosophila screenings for cell 
cycle mutants (3-5), and was later shown to phosphorylate endosulfine (Ensa) and 
Arpp19, two small proteins that when phosphorylated function as PP2A-B55 inhibitors 
(6, 7). Depletion of Greatwall in flies and Xenopus leads to defective chromosome 
condensation and segregation, as a consequence of the hyperactivation of PP2A-B55 
complexes, and the subsequent dephosphorylation of cyclin-dependent kinase 1 (Cdk1) 
substrates (4, 8). Less is known about the physiological relevance of the mammalian 
Mastl orthologue although knockdown and knockout assays suggest that it also 
participates in chromosome condensation and the maintenance of the mitotic state in a 
PP2A-B55-dependent manner (9-13). 
 Before the functional role of Mastl was studied in mammalian cells, a missense 
mutation in the human MASTL locus (located in chromosome 10p11-12) was found to 
perfectly segregate with nonsyndromic autosomal dominant thrombocytopenia, also 
known as thrombocytopenia-2 (THC2) (14). These patients were characterized by 
incomplete differentiation of megakaryocytes and moderate thrombocytopenia with 
certain propensity towards easy bruising and minor bleeding (15, 16). The mutation, a 
substitution of cytosine for guanidine (G to C) at nucleotide position 565, was present in 
all thrombocytopenic family members, causing a predicted substitution of aspartic acid 
for glutamic acid (E167D) in the human MASTL gene (14). In addition to the E167D 
substitution in MASTL, additional mutations in two genes in the THC2 region of 
chromosome 10p11-12 have been linked to congenital thrombocytopenia. These include 
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specific mutations in ACBD5 and the 5' UTR of ANKRD26, the ankyrin repeat domain 26 
gene (17). ANKRD26 mutations are the most frequent finding in THC2 patients (18) and 
the three affected genes are very close in human chromosome 10p12.1 (ACBD5-MASTL-
YME1L1-ANKRD26; centromeric to telomeric), raising questions on the relative 
contribution of MASTL mutations to thrombocytopenia (17, 19). 
 In order to get new insights into the biological significance of Mastl in mammalian 
tissues, we have generated mutant mice with specific ablation of the Mastl gene in mature 
megakaryocytes as well as a new knockin model carrying the thrombocytopenia-
associated mutation (E166D in the mouse). This mutation in Mastl does not result in 
reduced activity as originally thought (14), but is accompanied by increased 
phosphorylation of Cdk/PP2A substrates, suggesting a gain-of-function alteration that 
results in decreased PP2A activity. Whereas genetic ablation of Mastl results in deficient 
maturation of megakaryocytes in vivo, Mastl E166D mutant mice display defective 
dynamics in the actin cytoskeleton during platelet activation accompanied by an altered 
pattern of protein phosphorylation. These defects can be mimicked by PP2A inhibition 
and partially rescued by downregulating critical kinases involving in outside-in signaling. 
These results suggest a specific contribution of Mastl mutations in human 
thrombocytopenia and unveil an unexpected function for Mastl in sustaining actin 






Mastl deficiency, but not the E166D mutation, results in defective maturation in 
megakaryocytes 
We first made use of a conditional allele [Mastl(lox)] generated in our laboratory (12) in 
which exon 4, carrying essential domains for kinase activity, can be deleted upon 
activation of Cre recombinase resulting in a Mastl null allele (Figure 1A). Since 
homozygous germline ablation of Mastl [Mastl(–/–)] results in early embryonic lethality 
(12), we decided to specifically ablate Mastl in mature megakaryocytes and platelets by 
using Pf4-Cre transgenic animals (20), thus generating Pf4-Cre; Mastl(/) mice [from 
now on Mastl(/)]. To mimic the alteration found in thrombocytopenia, we also 
generated a knockin allele carrying the orthologue mutation found in human patients 
(corresponding to E166D in the mouse; Mastl(ED) allele; Figure 1B). Whereas deletion 
of exon 4 in knockout Mastl(/) mice results in a frameshift preventing the generation 
of transcripts or protein, Mastl(ED/ED) knockin mice express normal levels of mutant 
mRNA (Figure S1A) or protein (Figure 1C) in platelets or megakaryocytes. 
Mastl(/) and Mastl(ED/ED) mice were viable and fertile and displayed no overt 
abnormalities. The development of the hematopoietic system and their progenitors was 
normal in these models (Figure S1B). However, both mutant mice displayed reduced 
platelet counts in peripheral blood [~20% reduction in Mastl(/) and ~15% reduction in 
Mastl(ED/ED) mice] and a significant percentage of 8-12-week-old animals with reduced 
(<700 x 103 platelets/l blood) counts of platelets (Figure 1D, E). Whereas 
thrombocytopenia was more obvious in Mastl(/) mice, the trend observed in young 
Mastl(ED/ED) was conserved in older (50-old) mice as well as in heterozygous 
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Mastl(+/ED) mutant mice (Figure S1C,D). Finally, although the mean volume of platelets 
was not affected in these mutants (Figure S1E), levels of TPO were slightly elevated in 
Mastl(/) and Mastl(ED/ED) mice (Figure 1F), suggesting the presence of physiological 
defects in platelet number or function. 
To understand the cellular basis of these defects we next analyzed the maturation 
of megakaryocytes in vivo. Mastl(/) megakaryocytes in the bone-marrow displayed 
decreased expression of Von Villebrand Factor (VWF), a glycoprotein increasingly 
produced during maturation of these platelet-producing cells (Figure 1G). This defect 
however was not obvious in Mastl(ED/ED) mice. Mastl(/) mice also displayed reduced 
levels of fully-matured megakaryocytes (as scored by double CD41+ CD42+ staining) in 
the bone marrow (Figure 1H), although the ploidy of these cells was not affected (Figure 
1I). Mastl(ED/ED) mutants, however, did not display defects in neither VWF expression, 
CD41/CD42 levels, nor ploidy (Figure 1G-I). 
Altered platelet function in Mastl-null and Mastl E166D mice 
Circulating platelet counts reflect the balance between platelet production and clearance. 
We therefore tested platelet function by submitting Mastl mutant mice to different assays. 
We first investigated circulating half-life of platelets by the administration of a Dylight 
488-labeled anti-CD42c antibody. Both Mastl-deficient and Mastl E166D mice displayed 
a significant reduction in circulating half-life (Figure 2A), suggesting that increased 
clearance also contributes to the thrombocytopenia observed in Mastl-deficient mice, and 
may explain the defects in platelet counts in Mastl(ED/ED) mice. We did not find 
evidences for increased clearance of VWF-positive cells in liver sections (Figure S2A) or 
for protein desialylation using Maackia amurensis lectin (MAL1) or Ricinus communis 
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Agglutinin I (RCA-1) binding assays (Figure S2B). However, both Mastl(/) and 
Mastl(ED/ED) platelets displayed increased levels of Anexin V (Figure S2C), suggesting 
apoptosis as a potential mechanism to explain increase platelet clearance in these models. 
In agreement with reduced platelet counts, both Mastl(/) and Mastl(ED/ED) mice 
displayed increased bleeding time (Figure 2B) and defective clot retraction (Figure 2C). 
 We further evaluated the differences between these two models by inducing 
pulmonary embolism by intravenous injection of collagen and epinephrine. Lack of Mastl 
in the Mastl(/) model resulted in a significant protection of death in this model, in 
correlation with a reduced number of thrombi observed in the lungs (Figure 2D,E). 
Surprisingly, the presence of the Mastl E166D mutation resulted in the opposite 
phenotype: accelerated death accompanied by abundant and large thrombi in the lungs. 
In an independent model in which ferric chloride (FeCl3) was used to induce vascular 
injury in the context of an aseptic closed vascular system, lack of Mastl resulted in slightly 
increased vessel patency, whereas Mastl E166D mice displayed accelerated vessel 
occlusion in the presence of large thrombi (Figure 2F,G). Although Mastl(/) mice 
displayed lower count of peripheral platelets than Mastl E166D mutants, the differences 
found in these in vivo assays suggest a fundamental difference in the defects caused by 
the lack of Mastl or the presence of the thrombocytopenia-associated mutation. 
 
Functional defects in mutant platelet activation and spreading 
To investigate the basis for the differences between the two Mastl mutant platelets, we 
tested the response of these cells to several stimuli. No significant differences were 
observed in the aggregation of Mastl(ED/ED) platelets in response to thrombin (Figure 
3A,B) or collagen (data not shown), whereas Mastl-deficient platelets were significantly 
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inefficient in these assays. Exposure of isolated platelets to thrombin did not result in 
differences in the levels of high-affinity activated integrin IIb3 (fibrinogen receptor or 
CD41a), suggesting no defects in the early inside-out pathway in mutant platelets (Figure 
3C). However, whereas binding to fibrinogen was deficient in Mastl(/) platelets, it was 
enhanced in Mastl(ED/ED) mutant platelets perhaps suggesting a hyper-stabilization of 
fibrinogen-receptor complexes or deficient downstream events in the knockin model 
(Figure 3D). Both Mastl(/) and Mastl(ED/ED) platelets showed a defect in the 
generation of actin fibers after stimulation with fibrinogen when compared to control 
platelets, indicating defects in cytoskeletal dynamics in both models (Figure 3E). 
Fibrinogen uptake, a process that depends on endocytosis as well as re-organization of 
the actin cytoskeleton, was also deficient in Mastl(/) and Mastl(ED/ED) platelets, in 
line with the possible defects in outside-in signaling and/or cytoskeletal dynamics in these 
mutant cells (Figure 3F). All together, these data suggested cytoskeletal alterations in 
Mastl-mutant platelets, accompanied by deficient or enhanced signaling in Mastl(/) or 
Mastl(ED/ED) platelets, respectively. 
To functionally validate the observed defects in cytoskeletal regulators, we next 
monitored the morphological changes during platelet activation using electron 
microscopy and fluorescence-guided studies. Resting Mastl(ED/ED) platelets were 
indistinguishable from control cells in their size or granule composition (Figure 4A). 
However, these mutant cells formed bigger aggregates after activation with thrombin and 
displayed a specific defect in the formation of lamellipodia, a structure typically formed 
of a dense and dynamic network of actin filaments (Figure 4B), in agreement with defects 
in actin cytoskeleton dynamics. We next monitored cytoskeletal changes during platelet 
activation by thrombin on fibrinogen-coated surfaces at different time points by 
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immunofluorescence. In resting conditions, platelets are characterized by the presence of 
a ring of microtubules and a diffuse actin staining. After thrombin activation, these 
cellular components are re-distributed to form tight rings of constricted microtubules and 
actin filaments thus favoring first the formation of filopodia and later lamellipodia 
characteristic of cell spreading (Figure 4C). In Mastl-deficient platelets, this process 
occurred with delayed kinetics. The presence of Mastl E166D, however, resulted in the 
rapid formation of long pseudopods with abundant microtubules after activation. The 
filaments of actin were not formed and platelets maintained these hyper-stabilized 
microtubule structures, ultimately leading to the formation of big aggregates at later time 
points (Figure 4C). As previously reported (21), this phenotype was reminiscent of that 
obtained after the inhibition of PP2A phosphatases in wild-type platelets (Figure 4D,E), 
suggesting that the Mastl E166D mutation may result in decreased PP2A activity.  
Mastl E166D functions as a gain-of-function mutation 
The MASTL E167D mutation was originally proposed as a loss-of-function mutation 
(14). However, the similarities between PP2A inhibition and the Mastl E166D mutation 
during platelet spreading suggests that this mutation may rather confer increased 
inhibitory activity to Mastl over PP2A. To understand the intrinsic effect of the E166D 
mutation we first performed kinase assays after transfection of exogenous cDNAs in 
human 293T cells. As indicated in Figure S3A, the activity of Mastl on substrates or its 
autophosphorylation decreases when using a standard kinase-dead mutation in this 
protein (D155A mutant). However, the thrombocytopenia-associated mutant (E166D) 
was not defective in this assay and resulted in slightly higher levels of both 
phosphorylation of myelin basic protein and autophosphorylation (Figure S3A). We also 
generated mouse embryonic fibroblasts (MEFs) carrying the E166D mutation in the 
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endogenous locus [Mastl(ED/ED]. As shown in Figure S3B, Mastl immunoprecipitates 
from Mastl(ED/ED) MEFs displayed slightly increase in MBP phosphorylation when 
compared to control samples. 
Mastl is well characterized as a kinase required for the maintenance of the mitotic 
state by inhibiting mitotic PP2A-B55 complexes thus preventing the dephosphorylation 
of Cdk substrates (8, 9, 11, 12, 22). We therefore evaluated the relative functionality of 
the endogenous Mastl E166D mutant by testing its ability of supporting the mitotic state 
in dividing MEFs. As shown in Figure S3C, the presence of the Mastl E166D mutation 
resulted in increased phosphorylation of Cdk substrates (in agreement with reduced PP2A 
activity) after stimulation of quiescent cells with serum. These differences were not a 
consequence of differential progression through mitosis as determined with cyclin B1 and 
phosphorylation of histone H3. Similar results were obtained in cells arrested in mitosis 
with taxol and released after inhibiting Cdk1 to induce mitotic exit. The 
dephosphorylation of Cdk substrates was reduced in Mastl(ED/ED) MEFs, in agreement 
with reduced PP2A activity, despite a similar kinetics in the exit from mitosis as 
determined by the loss of cyclin B1 or histone H3 phosphorylation (Figure S3D). These 
assays were performed in the presence of taxol to increase mitotic entry due to the 
difficulties in synchronization of primary MEFs and no differences in the duration of 
mitosis were observed (Figure S3E), suggesting a specific alteration in the increased 
phosphorylation of substrates rather than differences in mitotic cells or the duration of 
mitosis. 
Interestingly, the pattern of phosphorylation of MAPK-Cdk substrates 
(characterized by proline-directed phosphosites for which PP2A-B55 displays certain 
preference) was also inverted in Mastl-null versus Mastl E166D platelets (Figure 5A), 
confirming the data described in MEFs. All together, these assays indicate that the E166D 
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mutation does not prevent Mastl activity and, instead, may result in a functional gain-of-
function, at least in the phosphorylation of putative PP2A-B55 phospho-substrates. 
Differential phosphorylation of actin cytoskeleton proteins in Mastl E166D 
platelets 
To gain further insights into the phosphorylation changes of mutant platelets we 
performed a phospho-proteomics analysis in resting or activated platelets at different time 
points after exposure to thrombin (Figure 5B). 82,525 out of 127,584 peptides identified 
were phosphorylated (83% enrichment) belonging to 1542 phospho-proteins. 4328 
individual phospho-sites were precisely localized (Class I) in these proteins (Figure 5B 
and Supplementary Table 1). 
In resting Mastl(ED/ED) platelets, 65 residues (in 61 proteins) were 
hyperphosphorylated [log2 Fold Change(FC) Mastl(ED/ED)/Mastl(+/+) > 0.75] when 
compared to control platelets, with an enrichment [False Discovery Rate (FDR)<0.005] 
in KEGG pathways related to membrane signaling, focal adhesion and cytoskeleton 
(Figure 5C and Supplementary Table 2). 104 residues (85 proteins) were 
hypophosphorylated [log2FC Mastl(ED/ED)/Mastl(+/+) < 0.75] in these mutant platelets 
with no specific KEGG pathway or GO biological process enriched in that set of proteins. 
A similar comparison in Mastl(/) vs. Mastl(+/+) platelets showed no enriched pathway 
in the hyperphosphorylated proteins whereas focal adhesion was enriched (FDR<0.001) 
among the hypophosphorylated proteins (Figure 5D and Supplementary Table 3).   
The bulk of phosphorylations increased 3 min after activation with thrombin and 
decreased at later time points in all different genotypes (Figure S4A). The signaling 
pathways involved in actin cytoskeleton reorganization upon focal adhesion was further 
hyperphosphorylated in Mastl(ED/ED) versus Mastl(+/+) platelets (121 residues in 95 
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proteins hyperphosphorylated; log2FC ED/WT>0.75) 3 min after the exposure to 
thrombin (Figure S4B), whereas no special pathway was enriched among the proteins 
hyperphosphorylated in Mastl(/) platelets (Figure S4B and Supplementary Table 4). 
Analysis of the hyperphosphorylated sequences in Mastl(ED/ED) resting platelets 
showed high frequency of CAMKII and PKA/PKC motifs with a smaller representation 
of [S/T]-P phospho-residues (Figure 5E), a sequence preferentially dephosphorylated by 
PP2A-B55 complexes (23). Three minutes after activation with thrombin, [S/T]-P 
phospho-residues were much enriched in activated Mastl(ED/ED) platelets compared to 
control cells (Figure 5E).  
A combined analysis of sequences hyperphosphorylated in both resting and 3-
min-activated platelets (42 phospho-residues in 43 proteins; log2FC ED/WT>0.75) 
suggested that focal adhesion and actin cytoskeleton were the most significant pathways 
with hyperphosphorylated components in resting and activated Mastl E166D platelets 
(Figure S5 and Supplementary Table 5). At later time points (15 and 45 min in the 
presence of thrombin), several additional pathways such as chemokine signaling, 
endocytosis, MAPK signaling pathway or inositol phosphate metabolism were also 
deregulated (Supplementary Tables 6 and 7).  
The results obtained in functional assays (Figures 2-4) and proteomic studies 
(Figure 5) suggested specific alteration of phospho-proteins, including those with proline-
directed phosphosites, involved in outside-in signaling downstream of integrin IIb3 
and in actin re-organization. The catalytic subunit of PP2A is known to associate 
constitutively with the integrin IIb3 preventing spontaneous outside-in signaling (24). 
Binding of fibrinogen to IIb3 leads to decreased integrin-associated PP2A activity, 
thereby favoring the phosphorylation of downstream targets such as the 
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enabled/vasodilator-stimulated phosphoprotein (Vasp), a critical regulator whose 
dephosphorylation is required for the dismantling of filopodia in order to form the 
lamellipodia required for spreading (25, 26). In Mastl(ED/ED) platelets, these changes 
were accompanied by enhanced activation of critical regulatory kinases such as protein 
kinase C (Pkc), Src or Fak (Figure 6 and S6A). Activation of these pathways likely 
resulted in increased phosphorylation of Vasp in both S157 and S322, which are known 
to increase stress fiber and filopodia formation (27), as well as the regulatory light chain 
of myosin II (Mlc2), a reporter of active re-organization of the actomyosin cytoskeleton. 
Inhibition Pkc, Pka or Ampk, three upstream kinases activated by IIb3 during outside-
in signaling and involved in Vasp phosphorylation (25, 28, 29), prevented Vasp 
hyperphosphorylation and downstream events in Mastl(ED/ED) platelets (Figure 6). In 
addition, treatment of wild-type platelets with the PP2A inhibitors fostriecin (Figure 6) 
or okadaic acid (Figure S6B) resulted in hyperactivation of these signaling regulators to 
similar extent to that found in Mastl(ED/ED) platelets.  
Functional relevance of altered actin dynamics in Mastl E166D platelets 
The finding that actin regulatory networks are deregulated during the activation of 
Mastl(ED/ED) platelets prompted us to evaluate the possible relevance of actin 
deregulation in the phenotypes observed in these mutant mice. Treatment of platelets with 
cytochalasin D, a compound that prevents actin polymerization, resulted in a significant 
increase in the formation of long pseudopods with abundant microtubules, mimicking the 
aberrations observed in Mastl E166D mutant platelets (Figure 7A). On the other hand, 
cytochalasin D resulted in increased cell death in wild-type platelets but it did not enhance 
the increased cell death levels observed after the activation of Mastl(ED/ED) platelets 
(Figure 7B). Interestingly, this compound partially rescued the increased cell death 
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observed in Mastl-null platelets. Jasplakinolide, a compound that promotes actin 
polymerization and prevents its disassembly, resulted in different aberrations in wild-type 
platelets, characterized by aberrant lamellipodia (Figure 7A). Interestingly, jasplakinolide 
partially rescued cell death in Mastl E166D mutant platelets but did not have a significant 
effect in Mastl-null platelets (Figure 7B).  
We next asked whether the abnormal behavior of Mastl(ED/ED) platelets could 
be rescued by inhibiting critical kinases upstream of Vasp and Mlc2 phosphorylation and 
actin cytoskeleton re-arrangements. Indeed, treatment of Mastl(ED/ED) platelets with 
Ampk, Pka and Pkc inhibitors rescued the formation of the abnormal pseudopod-like 
structures observed after thrombin-dependent activation of Mastl(ED/ED) platelets in a 
fibrinogen-coated surface (Figure 7C).  
We finally tested the effect of these kinase and phosphatase inhibitors in blood 
coagulation in vivo, As shown in Figure 8A, PP2A inhibition enhanced 
thromboembolism formation in wild-type mice thereby mimicking the effect of the Mastl 
E166D mutation (compare to Figure 2D). On the other hand, treatment of Mastl(ED/ED) 
mice with Ampk, Pka and Pkc inhibitors delayed embolism formation (Figure 8B) as well 
as embolism-induced death (Figure 8C) in the presence of the thrombocytopenia-
associated mutation. All together, these data suggest that Mastl E166D mutant platelets 
display an aberrant phosphorylation pattern that may contribute to defective platelet 
function and thrombocytopenia. 
DISCUSSION 
The Ser/Thr kinase Mastl has emerged as an essential module in the inhibition of cell 
cycle phosphatases, thus ensuring the maintenance of critical phospho-residues during 
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mitosis (1, 2). In the absence of Mastl, PP2A-B55 activity raises resulting in deficient 
phosphorylation of mitotic proteins. In yeast, Mastl homologues are involved in nutrient 
sensing or the regulation of transcription during quiescence or meiosis in a PP2A-
dependent manner (30, 31). Whether Mastl plays any role in mammalian postmitotic cells 
remains unexplored. 
 The identification of a missense mutation in the human MASTL gene in patients 
with thrombocytopenia type II (THC2; MIM 188000) (14, 16) suggested a putative role 
for this kinase either during the endomitotic process in megakaryocytes or in platelet 
function. The mutation in MASTL (E167D) perfectly segregated with thrombocytopenia 
affected individuals and it was not present in unaffected family members of unrelated 
individuals. Subsequent studies in zebrafish indicated reduced thrombocyte levels upon 
Mastl knockdown (32) although these studies were performed using specific morpholinos 
to eliminate Mastl expression, and the relevance of the thrombocytopenia-associated 
point mutation remained unclear. Our data using conditional mouse models or a knockin 
expressing the E166D (homologous to E167D in humans) mutant suggest that, whereas 
Mastl deficiency leads to defective maturation in high-ploidy megakaryocytes, Mastl 
E166D megakaryocytes show no obvious alterations in these platelet precursors. Mastl 
ablation does not prevent mitotic entry in mammalian cells (12) and Mastl-null 
megakaryocytes are able to reach normal ploidy levels, probably reflecting the fact that 
proper chromosome condensation or segregation is not required for endomitosis, 
similarly to what reported in Aurora B-null megakaryocytes (33). 
Interestingly, Mastl(ED/ED) mice display mild thrombocytopenia characterized 
by normal platelet size and volume, and increased levels of TPO, mimicking some of the 
characteristics of THC2 patients (16). THC2 patients are also characterized by other 
phenotypes not reproduced in Mastl E166D mice, such as defective polyploidy and 
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megakaryocyte differentiation (16), two phenotypes that are frequently attributed to 
specific nucleotide substitutions in the adjacent ANKRD26 gene. In fact, THC2 is now 
considered to be mostly a consequence of monoallelic single nucleotide substitutions in 
the 5’-UTR of the ANKRD26 gene (17, 18). These mutations lead to impaired binding of 
the transcription factors RUNX1 and FLI1 resulting in ANKRD26 overexpression, 
increased MAPK signaling and defective megakaryocyte maturation and proplatelet 
formation (34). Due to the frequency of these ANKRD26 alterations and the fact that 
ANKRD26 and MASTL are neighbor genes in the THC2 locus at human chromosome 
10p11-12, it was unclear to what extent MASTL E167D was a passenger mutation or had 
any causal role in the development of this disease. 
Our findings showing that Mastl E166D mice display mild thrombocytopenia and 
defective platelet activation not only indicate a causative role for Mastl mutations in 
thrombocytopenia, but also suggests for the first time a cell-cycle-independent role for 
this kinase in mammalian tissues. During the cell cycle, Mastl specifically inhibit PP2A 
phosphatase complexes containing B55 (B55, , , ) regulatory subunits to counteract 
Cdk-dependent phosphorylation (8, 22). In platelets, PP2A counteracts major kinase 
pathways (PKC, CMK2, CK2)(21), associates with the cytoskeletal fraction under 
aggregating conditions (35), and regulates outside-in signaling with a significant effect in 
the focal adhesion pathway (36). PP2A is a critical inhibitor of the outside-in signaling 
pathway downstream IIb3 and PP2A inhibition is known to enhance IIb3 adhesion 
to fibrinogen and phosphorylation of downstream events (24). PP2A directly 
dephosphorylates critical signaling molecules during platelet activation, such as protein 
kinase C-zeta (PKCz)(37) or VASP (24, 38). Inhibition of PP2A leads to defective 
spreading after activation with thrombin resulting in cells with long pseudopods with 
hyperestabilized microtubules (21), similar to what observed in Mastl E166D platelets 
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(Figure 4). Inhibition of PP2A in interphasic cells is known to induce a similar phenotype 
resulting in short dynamic microtubules typical of mitosis (39), suggesting certain 
parallelism in the mechanism of action of PP2A in preventing hyper-stabilized 
microtubules both in platelet and pre-mitotic cells.  
The exact mechanisms that regulate Mastl kinase activity are not well established. 
However, glutamine 166 is predicted to be close to the C-terminal tail required for 
activation of the kinase (40, 41), thus suggesting that the substitution of E by D may lead 
to different affinities for the activating tail. The common phenotypes induced by Mastl 
E166D and PP2A inhibition suggests that the E166D is not a loss-of-function mutation 
as originally suggested based on a similar mutation (E-to-D) in the tyrosine kinase Jak2 
(E1046D) shown to abolish kinase activity (42). In fact, our data suggest that Mastl 
E166D may be a functional gain-of-function alteration based on a) increased 
phosphorylation of proline-directed sequences (frequently dephosphorylated by PP2A-
B55 phosphatases) in fibroblasts (Figure S3) and platelets (Figure 5A), b) functional 
assays in fibroblasts (Figure S3), c) activation of signaling pathways (Figure 6), and d) 
the fact that PP2A inhibition mimics its effects in platelet spreading (Figure 4D,E) and a 
model of pulmonary embolism (Figure 8A). However, to what extent the defects observed 
in Mastl-mutant platelets are a direct consequence of differences in PP2A activity or are 
due to alterations in other putative Mastl substrates is unclear at the moment.  
Overall, the analysis of the MASTL thrombocytopenia-associated mutation in 
platelets has uncovered a new function for MASTL in the regulation of actin dynamics in 
postmitotic cells. Given the relevance of MASTL in cancer therapy (43), whether this 
function also contributes to cytoskeletal dynamics in proliferating or tumor cells is an 
intriguing possibility that deserves further research. Our data suggest that the MASTL 
E167D mutation may contribute to thrombocytopenia by altering the dynamics of platelet 
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activation as a consequence of deregulated phosphorylation events affecting the outside-
in pathway and actin cytoskeleton changes. The pathogenic effect of this mutation can be 
prevented by inhibiting critical outside-in kinases, an observation with putative 
implications for THC2 patients carrying this mutation. 
METHODS 
Generation of mutant mice 
The conditional loss-of-function model of Mastl was generated by flanking exon 4 of the 
murine Mastl locus with loxP sites (Figure 1A) (12). These mice were crossed with Pf4-
Cre transgenics (20) to generate megakaryocyte-specific loss of Mastl. The new 
thrombocytopenia knockin model was generated by replacing the wild-type allele with a 
mutant allele carrying the E166D mutation (Figure 1B), analog to the E167D mutation 
found in human thrombocytopenia. Recombinant ES cells harboring this allele were 
electroporated into developing morulas and the resulting mice were crossed with Actin-
Flp transgenics to generate Mastl(+/E166D) mice. Mice were maintained in a CD1 x 
C57BL/6J x 129Sv/J mixed background. Mice were housed in the pathogen-free animal 
facility of the Centro Nacional de Investigaciones Oncológicas (CNIO, Madrid) 
following the animal care standards of the institution. These animals were observed on a 
daily basis and sick mice were killed humanely in accordance with the Guidelines for 
Humane End Points for Animals used in biomedical research.  
For histological examination, samples were fixed in a solution of 4% of 
paraformaldehyde, embedded in paraffin and cut in 2.5-µm sections. Sections were then 
stained with hematoxylin and eosin (H&E) or Cartair’s staining with the Carstais’s stainig 
kit (Electron Microscopy Sciences, CatnNo26381-Series), following the manufacture’s 
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protocol. For immunohistochemistry, a von Willebrand factor antibody (FVIII, Dako; 
1:2000) was used. Sections were examined using a Nikon ECLIPSE 90i microscope using 
a CFI Plan Apo Lambda 4X/0.2 WB20 and a CFI Plan Apo Lambda 20X/0.75 DIC/N2 
WB1.0, and processed using the ImageJ software. Further details in the antibodies used 
in this work are included in Supplementary Table 8. 
 
Blood analysis 
For platelet counts, blood sampling was performed from mandibular vein, collecting the 
blood into EDTA-coated tubes. Blood cell counts were assessed on an automated analyzer 
(Abacus Jr Vet, Vienna, Austria). Plasmatic TPO levels were measured with a Quantikine 
Mouse Thrombopoietin ELISA Kit (R&D Systems), following the manufacturer´s 
guidelines. Plasma from Cdc20-deficient mice (33), which display severe 
thrombocytopenia were included as a control. 
 
Isolation and analysis of hematopoietic cells 
Cells from the bone marrow or fetal liver were isolated as indicated in (33). The tibia and 
femur were isolated from 8-12-week old mice and bone marrow was flushed out by the 
addition of ice-cold PBS buffer (PBS, 0.5% BSA, 5 mM EDTA) through the lumen of 
the bone. Marrow was mechanically disrupted to achieve single cell suspension followed 
by filtering through a 40 m nylon strainer to remove bone debris and subsequently 
subjected to erythrocyte lysis in ACK lysis buffer (150 mM ammonium chloride, 1 mM 
potassium bicarbonate, 0.1 mM EDTA; 90 s on ice). The lysis was stopped by the addition 
of 10 ml PBS buffer and cells were centrifuged at 200 g for 10 minutes. Cells were 
counted and subjected either directly to surface antigen staining for flow cytometry 
analysis or to lineage depletion with the MACS (magnetic cell sorting) Hematopoietic 
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Progenitor (Stem) Cell Enrichment Set (Miltenyi Biotec) according to manufacturer’s 
protocol.  
Megakaryocytes were isolated from bone marrow samples by staining with 
monoclonal allophycocyanin (APC)-CD41 antibody (BD Biosciences), followed by 
incubation with Anti-APC MicroBeads (Miltenyi Biotec). The cell suspension was then 
loaded onto a Large Cell separation MACS® Column and megakaryocytes were positive 
selected in a MACS Separator and columns (Miltenyi Biotec). For fetal liver derived 
megakaryocytes, cells were obtained from whole livers recovered from mouse fetuses 
between embryonic days 12.5 and 13.5. Single-cell suspensions were prepared by 
successive passage through 19-, 22-, and 25-gauge needles. Lin- cells were grown in 
Dulbecco’s modified Eagle’s medium (DMEM; GIBCO) supplemented with antibiotics 
and 10% fetal bovine serum (FBS), and stimulated with 50 ng/ml murine TPO 
(PeproTech) during at least 5 days. Ploidy of derived megakaryocytes was analysed at 
day 1, 3 and 5 of differentiation by staining with Fluorescein-5-isothiocyanate (FITC) 
anti-CD41 and 1 μg/ml of 4′,6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich) in 
methanol-fixed derived megakaryocytes. Ten thousand-gate events were collected per 
experiment in a BD FACSCanto™ II cytometer (BD Biosciences). Data was analyzed 
using FlowJo Version 8.8.7 software (TreeStar).  
To quantify bone marrow hematopoietic stem cells, freshly cells from the bone 
marrow were stained with phycoerythrin (PE) anti-CD34, Alexa Fluor 488 anti-IL7Ra, 
peridinin chlorophyll Protein Cyanin 5.5 (PerCP-Cy 5.5 anti–Sca-1, allophycocyanin-H7 
(APC-H7) anti-cKit, phycoerythrin-cyanin 7 (PE-Cy7), anti-FcR and APC-labeled 
lineage cell detection cocktail (all from BD Biosciences). To determine ploidy from bone 
marrow megakaryocytes, methanol-fixed bone marrow cells were stained with APC anti-
CD42, FITC anti-CD41 and 1 μg/ml DAPI. In all assays, 10,000-gate events were 
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collected per sample in a BD FACSCanto™ II cytometer (BD Biosciences). Data were 
analyzed using FlowJo Version 8.8.7 software (TreeStar). The details of the antibodies 
used are listed in Supplementary Table 8. 
Platelets were isolated as described previously described (44). Briefly, mice were 
anesthetized with ketamine (100 mg/kg) and xylacine (10 mg/kg), and whole blood was 
drawn from the inferior vena cava into a syringe containing acid citrate dextrose (1 
volume of anticoagulant/9 volumes of blood). Blood was mixed with one volume of 
modified HEPES-Tyrode’s buffer (140 mM NaCl, 2 mM KCl, 12 mM NaHCO3, 0.3 mM 
NaH2PO4, 1 mM MgCl2, 5.5 mM glucose, 5 mM HEPES, 2 mM EGTA and 0.035% BSA, 
pH 6.7) and it was centrifuged at 150 g for 2 min to obtain platelet-rich plasma (PRP). 5 
nM of Prostaglandin E1 (PGE1; Sigma-Aldrich) was then added and platelets were 
pelleted by centrifugation at 1,500 g for 4 minutes at 37 °C. Platelet pellets were finally 
suspended in modified HEPES-Tyrode’s buffer without EGTA and BSA (pH 7.38) but 
in the presence of 0.02 U/ml of Apyrase (Grade VII; Sigma-Aldrich). Platelets were 
counted and pooled at a density necessary for each experiment. 
 
mRNA expression analysis 
mRNA extraction from platelets was performed following the protocol described for the 
commercial reactive Trizol® (Invitrogene). RNA reverse transcription was performed 
with the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems), using 
500 ng of total RNA in each reaction and following the protocol described in the kit. 
Mastl mRNA levels were measured by real-time PCR using SYBR Green PCR Master 
Mix (Applied Biosystems). For amplification, primers placed in targeted region (Mastl 
exon 3/4) were used: forward, 5′-AGACTACCTGCACAGACATGGA-3′ and reverse, 
5′-TTGGAAAGGCAAAATCTGTCAGT-3′; and Gapdh: forward, 5′-
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TCAACAGCAACTCCCACTCTTCCA-3′ and reverse, 5′-
ACCCTGTTGCTGTAGCCGTATTCA-3′. Amplification was performed in an Applied 
Biosystems 7900HT Fast Real-Time PCR System, using the following conditions: initial 
activation 50ºC for 20 s, initial denaturation at 95ºC for 600 s and 45 cycles of (95ºC for 
15 s, 60ºC for 40 s, and 72ºC for 20 s), at transition rates of 4.8ºC/s, except for annealing 
which was 2ºC/s. The program for melting curve analysis was 95ºC for 10 s, 65ºC for 30 
s with a 2.5ºC/s transition rate, and then ramping to 95ºC at a transition rate of 0.1ºC/s. 
Ct values were determined automatically and analyzed using the by the SDS Software 
2.2. Gapdh mRNA levels were used as an internal control for normalization. 
 
Analysis of platelet lifespan  
To analyze platelet lifespan, mice were injected i.v. with 0.2 mg/kg of DyeLight488-
labelled anti-CD42c (GPIb) antibody (Emfret Analytics, Germany). After 1 h, 10 l of 
whole blood from maxillary vein was collected into EDTA-coated tubes. Whole blood 
was diluted (1/25) in PBS and the PRP was obtained by centrifugation at 1,500 g for 5 
minutes. PRP was then stained with APC anti-CD41 (eBiosciences) and, after further 
dilution with PBS (1/2), samples were analyzed. Ten thousand CD41+-gate events were 
collected per sample in a BD FACSCanto™ II cytometer (BD Biosciences). Data was 
analyzed using FlowJo Version 8.8.7 software (TreeStar) and results were expressed as 
percentage of DyeLight+ events respect to the total of CD41+ events.  Platelet counts were 
obtained daily for 5 days at the same time.  
 
Tail bleeding time and clot retraction 
Tail bleeding time measurements were performed as described earlier (45), with some 
modifications. Mice were anesthetized with an i.p. injection of ketamine (100 mg/kg) and 
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xylazine (20 mg/kg). The tip of the tail was cut and immediately immersed in PBS pH 
7.4 pre-warmed at 37°C. The mice and the pre-warmed tubes PBS were placed into an 
incubator at 37ºC for maintain them at the same temperature along the measurements. 
Bleeding time was defined as the time needed for the cessation of visible blood stream 
for two minutes. Monitoring of the bleeding times was stopped at 10 minutes by 
cauterizing the tails to prevent excessive loss of blood. 
 Clot retraction assays were performed as previously described (46). Washed 
platelets were counted and adjusted to 5x108 platelets/mL with Hepes Tyrode’s Buffer 
supplemented with 2 mM MgCl2, 2 mM CaCl2 and 2 mg/mL fibrinogen (Sigma-Aldrich). 
Clot retraction assays were performed at 37 ºC without stirring, in siliconized glass 
cuvettes with 400 µL of platelet suspension in the presence of 10 IU/mL of thrombin 
(Chrono-log Corp). Clots were monitored every 15 min up to 120 min after clot induction. 
The area of the clot was analyzed in each picture by Image J software 
(http://rsb.info.nih.gov/ij/). At the final time point, the clot exudate was collected and the 
wet clot weighed. 
 
Ferric chloride (FeCl3)-induced carotid artery injury 
These studies were performed essentially as reported previously (47, 48). Mice were 
anesthetized with isoflurane (Abbott Laboratories) and the left carotid artery was 
exposed.  A 0.5-1.0-mm strip of Whatman No. 1 filter paper soaked in 5% FeCl3 solution 
was applied to the surface of the adventitia for 3 min. Carotid blood flow was monitored 
with a miniature ultrasound flow probe (0.5VB, Transonic Systems) interfaced with a 
flowmeter (model T106, Transonic Systems) and a computerized data acquisition 
program (WinDaq, DATAQ Instruments). At the end of the 30-min flow-monitoring 
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period, mice were euthanized by cervical dislocation and the carotid artery was excised 
for histological purposes.  
 
Collagen/epinephrine-induced pulmonary thromboembolism 
To induce thromboembolism, mice were anesthetized as described in tail bleeding assays 
and a mixture of 0.5 mg/kg of equine collagen (Hormon Chemie, München, Germany) 
and 60 μg/kg of epinephrine (Sigma) was injected into the jugular vein. Most mice died 
within the first 15 min; otherwise, they were euthanized by cervical dislocation. 
Histological examination of the lungs was performed to determine whether vessels of the 
microcirculation were occluded by thrombi consisting of platelet aggregates formed in 
response to the epinephrine-collagen. When indicated, mice were treated with kinase or 
phosphatase inhibitors for 1 h before of the induction of pulmonary embolism. These 
drugs were administered by i.v. injection at the following doses: 0.5 mg/kg Fostriecin, 
0.2 mg/kg Dorsomorphin 2-HCl (Compound C analog), 1 mg/kg H89, 10 mg/kg Gö6983, 
0.5% DMSO or vehicle (10% PEG400; 0.16% Tween80; 1.6% propylene glycol). 
 
In vitro aggregation studies 
For aggregation studies of murine platelets, 500 µl of washed platelets at 5x108 platelet/ml 
were used. Optical platelet aggregation experiments were monitored by a turbidimetric 
method using an aggregometer (Chronolog 490 optical aggregometer) with continuous 
stirring at 1200 rpm at 37°C. A final concentration of 0.5 UI/ml of Thrombin and 5 μg/ml 
of collagen (Cronolog Corp.) were used as agonists for aggregation studies. 
 
Platelet Flow Cytometry assays 
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To determine integrin αIIbβ3 (GPIIb/IIIa) activation in mice platelets, 100 µl of 1x106 
platelets/mL of washed platelets were incubated for 15 min at RT with rat anti-mouse-
PE-CD41a (JON/A) alone (resting) o together 0.05 IU/mL of thrombin (activated). 
Reactions were stopped by addition of 400 μl PBS and samples were analyzed within 30 
minutes by FACS. The mean fluorescence intensity of mutant versus wild-type platelets 
was used to measure the activated conformation of mouse integrin αIIbβ3 (GPIIb/IIIa, 
CD41/CD61). 
Ex-vivo Fibrinogen binding (Fg-binding) and Fibrinogen Uptake (Fg-uptake) 
assays were performed following the protocol described previously (49) with minor 
modifications. Basically, 100 µl of 1x107 platelets/mL of washed platelets were 
supplemented with 0.15 mg/mL AlexaFluorTM488-conjugated human fibrinogen 
(Molecular Probes) and 2mM CaCl2. Platelets were then incubated for 30 minutes at 37 
ºC, fixed with 2% paraformaldehyde and analyzed by flow cytometry. To study Fg-
uptake, washed platelets (100 µl of 1x107 platelets/mL) were incubated with Fg-
AlexaFluorTM488 (0.15 mg/mL) at 37°C for 30 minutes. Platelets were fixed with 2% 
paraformaldehyde and, after addition of 0.04% trypan blue, analyzed by flow cytometry.  
For determination of intracellular F-actin levels, 100 µl of 1x107 platelets/mL 
were incubated with 0.05 IU/mL of thrombin for 3 and 15 min prior to fixation with with 
2% paraformaldehyde. Platelets were then permeabilized with 0.05% Triton X-100 and 
stained using 2 mM AlexaFluorTM488-phalloidin for 1h at RT. Platelets were washed 
twice with PBS and then analyzed by flow cytometry.  
Platelet surface sialylation and galactose exposure was analyzed by incubation of 
100 µl of washed platelets (1x107 platelets/mL) with rat anti-mouse-PECy7-CD41 and 
fluorescein-labelled Ricinus Communis Agglutinin I (FL-RCA I, used at final 
concentration of 0.5 g/ml ) or fluorescein-labelled Maackia Amurensis Lectin I (FL-
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MAL I, used at final concentration of 0.5 g/ml)(Vector Laboratories) for 45 min at RT. 
Platelets were washed with PBS twice and analyzed by flow cytometry. 
For annexin V staining,  ten million of platelets were suspended in 100 l of 1X 
Binding Buffer (0.01 M HEPES, pH 7.4; 0.14 M NaCl; 2.5 mM CaCl2) and incubated for 
1, 3 or 6 hours at 37 ºC. When indicated, platelets were also incubated in the presence of 
10 µM of Cytochalasin D (Sigma-Aldrich) or 5 µM of Jasplakinolide (Tocris). Staining 
was performed adding 5 l of APC-AnnexinV (BD Bioscience) and 1l of FITC-CD41 
[MWReg30] or FITC-CD9 [EM-04] (BD Bioscience) for 30 min at RT. Reaction was 
stopped by adding 400 µl of 1X Binding Buffer and it was immediately analyzed by flow 
cytometry.  
In all assays described above, 10,000 platelet-gate events were collected per 
experiment in a BD FACSCanto™ II cytometer (BD Biosciences). Data were analyzed 
using FlowJo Version 8.8.7 software (TreeStar) and MFI was use to evaluate Fg-binding, 
Fg-uptake, F-actin content, sialylation and Annexin V binding, respectively.   
 
Transmission electron microscopy 
Resting and thrombin (0.05 IU/mL, 15 min) activated platelets were fixed for 3 h at RT 
in 3% glutaraldehyde (vol/vol) in 0.4 M N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic 
acid buffer pH 7.4, washed and fixed again in aqueous 1% (wt/vol) osmium tetroxide, 
and embedded in Epon. Electron microscopy was performed with a JEOL 1230 




Analysis of mouse embryonic fibroblasts 
Mouse embryonic fibroblasts were isolated from E13.5 embryos and analyzed using 
routine cell cycle protocols (12). For flow cytometry analysis, cells were washed in PBS 
and fixed in ice-cold 70% ethanol. For identification of mitotic cells, cells were blocked 
using 3% bovine serum albumin (BSA) in PBS for 1 h followed by addition of MPM2 
antibody (Millipore, 1:200) in blocking solution. Antibodies were detected with 
AlexaFluor 594 (1:1000) and DAPI was used to stain nuclei. Cell cycle profiles were 
determined by FACSCanto II flow cytometry system (BD Biosciences). The data were 
analyzed with the FlowJo software v7.5. 
Biochemical assays 
Two hundred and fifty microliters of washed platelets at 5×108 platelets/ml were 
supplemented 0.05 IU/ml of Thrombin (Cronolog cop.) and incubated at 37 ºC for 
different times. Then, 250 µl of 2X RIPA lysis buffer (100 mM Tris-HCl pH 8.0; 0.2% 
SDS, 2% NP-40, 1% sodium deoxycholate) supplemented with a mixture of protease and 
phosphatase inhibitors (PhosSTOP and Complete Protease Inhibitor Cocktail, Roche 
Applied Science) were added. The homogenate was incubated in ice for 30 minutes and 
centrifuged at 13,000 g for 15 minutes at 4 ºC, collecting the supernatant. Protein lysates 
from MEFs were prepared as described previously (11). Total protein was quantified 
using a selective colorimetric detection by bicinchoninic acid commercial kit (BCA 
Protein Assay Reagent Kit, Pierce) and samples were boiled in Loading buffer (70% (v/v) 
0.5M Tris-HCl-0.4% (w/v) sodium dodecil sulphate pH 6.8, 30% (v/v) glycerol, 10% 
(w/v) SDS, 9.3% (w/v) dithioteitol, 0.012% (w/v) bromophenol blue and 10% (v/v) β-
mercaptoethanol) at 98 ºC for 10 minutes.  
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For western blot analyses, 50 g of total protein extract from murine platelets were 
analyzed by SDS-PAGE (4–15% Criterion™ TGX™ Precast Midi Protein Gel) before 
transfer to a nitrocellulose membrane. Membranes were blocked for 1 h at room 
temperature with 5% (w/v) of non-fatty milk in TBS-T (50 mM Tris-Cl, 100 mM NaCl, 
0.1% Tween-20, pH 7.4) and incubated overnight at 4 ºC with the indicated antibodies 
(Supplementary Table 8). All membranes were rinsed 3 times with TBS-T and incubated 
with secondary antibodies conjugated with HPR. Protein detection was done using the 
ECL Advance Western Blotting Detection System (Amersham Biosciences) and X-ray 
fim exposure, following the recommendations of the manufacturer. 
For in vitro kinase assays, HEK293 cells (ATCC) were transiently transfected 
with the indicated V5-tagged Mastl mutants. Cells were lysed in ELB buffer (50mM 
Hepes pH 7.5, 150 mM NaCl, 5mM EDTA, 1% NP-40) in the presence of protease and 
phosphatase inhibitors. Exogenous Mastl was immunoprecipitated with an anti-V5 
antibody (Invitrogen), and immunocomplexes were incubated in kinase buffer (20mM 
Hepes pH 7.5, 10 mM MgCl2, 1 mM DTT) in the presence of 50 µM ATP, 2 µCi 32P--
ATP and 2 µg of myelin basic protein (MBP) as a substrate, during 30 min at 30ºC. 
Samples were analysed by SDS-PAGE, transferred to a nitrocellulose membrane, and 
images were obtained by autoradiography. Quantifications were performed using a 
Phosphorimager. For measuring the activity of Mastl in MEFs, cells were lysed in ELB 
buffer and endogenous Mastl was immunoprecipitated with an anti-Mastl antibody 
(Abgent). Kinase assays were performed following the same protocol as described above. 





Cells were lysed using 7 M urea, 2 M thiourea, in 100 mM Hepes pH 7.5, supplemented 
with 1:1000 (v/v) of benzonase (Novagen) and 1:100 (v/v) of HaltTM phosphatase and 
protease inhibitor cocktail 100x (Thermo Fisher Scientific). Protein concentration was 
determined using the Pierce® 660nm Protein Assay (Bio-Rad) using BSA as standard. 
Then, samples (160 µg) were digested by means of the standard FASP protocol. Briefly, 
proteins were reduced (15 mM TCEP, 30 min, room-temperature), alkylated (50 mM 
CAA, 20 min in the dark, room-temperature) and sequentially digested with Lys-C 
(Wako) (protein:enzyme ratio 1:50, o/n at room-temperature) and trypsin (Promega) 
(protein:enzyme ratio 1:100, 6 h at 37 °C). Samples were labeled using iTRAQ® reagent 
8-plex following manufacturer’s instructions. Samples were mixed in 1:1 ratios based on 
total peptide amount, which was determined from an aliquot by comparing overall signal 
intensities on a regular LC-MS/MS run. The final mixture was finally desalted using a 
Sep-Pak C18 cartridge (Waters) and dried. 
Phosphopeptides were enriched using home-made TiO2 micro-columns. Briefly, 
peptides were resuspended in 6% TFA and 80% CH3CN and incubated for 20 min with 
TiO2 beads (10 µm particle size) (GL-Science) using a sample:TiO2 ratio of 1:2. Prior 
incubation, TiO2 beads were pre-conditioned with a solution of 20 mg/mL DHB in 80% 
CH3CN 6% TFA for 20 min. Then, beads were sequentially washed with 100 µL of 6% 
TFA and 10% CH3CN, 100 µL of 6% TFA and 100 µL of 40% CH3CN and 6% TFA and 
60% CH3CN. Finally, phosphopeptides were eluted first with 20 µL of 5% NH4OH and 
then with 20 µL 5% NH4OH in 10% CH3CN in the same vial. 
Phosphopeptides were fractionated offline by means of a high pH reverse phase 
micro-column. Samples were dissolved in phase A (20 mM NH4OH) and loaded into a 
tip containing 5 discs of C18 and the flow-through was collected to a vial. Peptides were 
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sequentially eluted by increasing the percentage of buffer B (20 mM NH3 in CH3CN) (i.e. 
4, 8, 12, 20, 60 and 80%).  Last three fractions were pooled together. 
LC-MS/MS was done by coupling a nanoLC-Ultra 1D+ system (Eksigent) to an 
Impact mass spectrometer (Bruker) via a Captivespray source (Bruker) supplemented 
with a nanoBooster operated at 0.2 bar/min with isopropanol as dopant. Peptides were 
loaded into a trap column (NS-MP-10 BioSphere C18 5 µm, 20 mm length, 
Nanoseparations) for 10 min at a flow rate of 2.5 µl/min in 0.1% FA. Then peptides were 
transferred to an analytical column (ReproSil Pur C18-AQ 2.4 µm, 500 mm length and 
0.075 mm ID) and separated using a 95 min gradient (buffer A: 4% ACN, 0.1% FA; 
buffer B: 100% ACN, 0.1% FA) at a flow rate of 250 nL/min. The gradient used was: 0-
2 min 6 % B, 2-80 min 30% B, 80.5-87.5 min 98% B, 88-95 min 2% B. The peptides 
were electrosprayed (1.35 kV) into the mass spectrometer with a heated capillary 
temperature of 180°C. The mass spectrometer was operated in a data-dependent mode, 
with an automatic switch between MS (80-1600 m/z) and MS/MS (80-1600 m/z) scans 
using a top 30 method (threshold signal ≥ 500 counts, z ≥ 2 and m/z ≥ 350). An active 
exclusion of 30 s was used. The precursor intensities were re-evaluated in the MS scan 
(n) regarding their values in the previous MS scan (n-1). Any m/z intensity exceeding 5 
times the measured value in the preceding MS scan was reconsidered for MS/MS. 
Peptides were isolated using a 2 Th window and fragmented using collision induced 
dissociation (CID) with a collision energy of 23-56 eV as function of the m/z value. 
For data analysis, raw files were processed with MaxQuant (v 1.5.8.3) using the 
standard settings against a mouse protein database (UniProtKB/Swiss-Prot and TrEMBL, 
August 2016, 43,965 sequences) supplemented with contaminants. 
Carbamidomethylation of cysteines was set as a fixed modification whereas oxidation of 
methionines, protein N-term acetylation and phosphorylation of serines, threnonines and 
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tyrosines as variable modifications. Minimal peptide length was set to 7 amino acids and 
a maximum of two tryptic missed-cleavages were allowed. Results were filtered at 0.01 
FDR (peptide and protein level). For phosphoproteome, the “phospho(STY)sites.txt” file 
was loaded in Perseus (v1.5.1.6) for further analysis. Phosphosites with a probability > 
0.75 and a score difference < 5 were considered as localized (Class I). Phosphosites with 
a log2FC ratio >0.75 or < -0.75 were considered as regulated. Over-representation of 
functional terms was performed with StringDB (50) using as background data set the 
platelets proteome (51) as background. A Fisher’s exact test with multiple test correction 
was used and only terms with an FDR below 5% were considered as statistically 
significant. 
The mass spectrometry proteomics data have been deposited to the 
ProteomeXchange Consortium via the PRIDE partner repository with the dataset 
identifier PXD009398.  
 
Platelet Spreading assays 
Spreading assays were performed as described previously (46). In brief, Lab-Tek™ 
Chamber Slides (Nunc) were coated overnight at 4ºC with 100 µg/ml of human fibrinogen 
(Sigma-Aldrich) in PBS, pH 8.0. Then, they were washed with PBS and blocked with 5 
mg/ml of heat-denatured BSA for 2 h at RT, and then washed again. Platelets at 1x108 
platelets/mL were incubated on the fibrinogen coated chambers and let to spread for 5, 
15, 30, and 60 min at 37ºC in presence of 0.05 IU/mL of thrombin. For actin inhibitors, 
platelets were allowed to adhere for 5 minutes and then, Cytochalasin D or Jasplakalodine 
were added at a final concentration of 10 µM and 5 µM, respectively, and let to spread 
for 15 minutes. After that, chambers were washed and adhered platelets were fixed with 
4% of paraformaldehyde (PFA) for 10 min. After washing, chambers were incubated with 
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100 mM Glycine for 5 minutes and washed. Then, adhered platelets were permeabilized 
with 0.2% Triton X-100 for 5 min, washed and blocked with 10% normal goat serum 
(Sigma-Aldrich) for 30 min. Platelets were incubated with anti--tubulin primary 
antibody, followed by secondary antibody AlexaFluor488 goat anti-mouse. 
AlexaFluor564-Phalloidin was used to stain F-actin. Images were acquired with a Leica 
TCS SP5 WLL confocal laser microscope using a HCX PLAN APO CS 63x/1.4 Oil 
Immersion or HCX PLAN APO CS 100x/1.4 Oil Immersion. For platelet morphology 
quantification, at least 150 platelets per sample were measured using Fiji software. 
Statistical Analysis 
Statistical analyses were performed using Prism software (GraphPad Software). Unless 
stated otherwise, all statistical tests of comparative data were done using Mann-Withney 
test or two-sided, unpaired Student's t tests when Welch’s correction when needed. For 
survival analysis, Log-rank (Mantel-Cox) Test with Bonferroni correction was applied. 
Data were expressed as means of at least three independent experiments ± SEM, with P 
< 0.05 considered statistically significant.  
Study approval 
All animal protocols were approved by the Instituto de Salud Carlos III/Comunidad de 
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Figure 1. Mild thrombocytopenia in Mastl(/) and Mastl(ED/ED) mice. A, 
Representation of the Mastl(lox) and Mastl() alleles used in this work. A Pf4-Cre 
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transgene was used to generate megakaryocyte-specific Mastl-null mice. B, Generation 
of the Mastl(E166D) [Mastl(ED) for brief] allele. The frt-neo_resistance-frt cassette was 
removed after crossing with Flp-expressing mice. White or orange triangles represent lox 
or frt sequences, respectively. C, Expression of Mastl in bone marrow CD41+ cells from 
mice with the indicated Mastl genotypes. Lysates from NIH3T3 cells were used as a 
control. Representative image from two independent experiments. D, Platelet levels in 
12-week old males (blue) or females (pink) with the indicated genotypes. The blue line 
indicates a concentration of 800x106 platelets/ml as a reference. E, The percentage of 
mice with less than 800x106 platelets/ml is shown (using mice from panel D). Males and 
females are represented in separated columns (right panel). F, Levels of thrombopoietin 
(TPO) in peripheral blood in the indicated mice. Cdc20-deficient mice, which display 
severe thrombocytopenia (33), are used as a control (n≥4 mice per genotype). G, 
Representative micrographs of bone marrow from mice with the indicated genotypes. 
H&E, hematoxylin and eosin; VWF, von Villebrand Factor. Images represent more than 
3 mice per genotype analyzed. Scale bars, 50 m. The quantification of the VWF signal 
in more than 100 megakaryocytes per genotype is indicated in the right panel. Bars 
indicate mean. H, Quantification of CD41 and CD42-positive cells in bone-marrow cells 
from mice with the indicated genotypes. I, Quantification of the ploidy in CD41+, CD42+ 
double positive cells from bone marrow cells of the indicated genotypes. No significant 
differences are found between the different genotypes (N=3 per genotype; bars indicate 
mean). In panels D-I, *, P<0.05; **, P<0.01; ***, P<0.001; ns, not significant (Student’s 








Figure 2. Altered platelet function in Mastl-mutant mice. A, Platelets were labeled with 
DyeLight488-labelled anti-CD42c (GPIb) antibody, then monitored for percentage of 
DyeLight488+ versus total CD41+ platelets, stained with an APC-labelled anti-CD41 
antibody. N=3 mice per genotype. B, Bleeding time (left) and number of re-bleedings 
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(right) in mice (N=12 per genotype) with the indicated genotypes. C, Clot retraction in 
the indicated genotypes. Representative images from 3 different mice per genotype are 
shown on the left. The plot represents the percentage of the area of the clot versus time 0. 
The histograms on the right show clot weight and volume exudate (mean ± SEM) after 
120 min. In panels A-C, *, P<0.05; **, P<0.01; ***, P<0.001; Student’s t-test. D, 
Survival of control and mutant mice after induction of pulmonary embolism using 
collagen. N=12 mice per genotype. **, P<0.01; Log-rank test with Bonferroni correction. 
E, Micrographs showing thrombi (arrows) and non-coagulated blood (asterisks). Images 
are representative from 3 mice analyzed. Scale bars, 100 m. F, Ferric chloride (FeCl3)-
induced carotid artery injury model. N=9 mice per genotype. **, P<0.01; Log-rank test 
with Bonferroni correction. G, Representative Carstairs' staining images of thrombi 
formed in the carotid artery after injury with 5% of FeCl3 from 3 mice analyzed. Scale 

















Figure 3. Platelet activation in Mastl(/) and Mastl(ED/ED) mutant mice. A, 
Representative light transmission aggregometry (LTA) curves of platelets with the 
indicated genotypes in the presence of 0.5 IU/mL of thrombin. B, Percentage of 
aggregation and slope of the aggregation curves from LTA assays. In A,B, N=4 mice per 
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genotype. C, Flow cytometry detection of activated mouse integrin IIb3 (CD41a) 
using the specific conformational antibody JON/A (N=3 mice per genotype). D, Soluble 
fibrinogen binding quantification by flow cytometry in washed platelets activated with 
0.05 IU/mL of thrombin for 30 minutes (N=3 mice per genotype). E, Quantification of F-
Actin content by flow cytometry in activated platelets with thrombin for 3 and 15 minutes, 
as indicated (N=3 mice per genotype). F, Quantification of platelet Fibrinogen-Uptake by 
flow cytometry of thrombin activated platelets in presence of AlexaFluor488-labelled 
fibrinogen (N=4 mice per genotype). In panels B-F, bars represent mean ± SEM; *, 





Figure 4. Platelet morphology and spreading properties in Mastl mutant mice. A,B, 
Representative electron microscopy images of resting (A) or activated (B; 0.05 IU/mL 
thrombin for 15 min) platelets from 3 mice with the indicated genotypes. Scale bars, 1 
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m. Plots represent mean ± SEM of the quantification of the area, circularity (0-1, being 
1 a perfect circle) and number of  and -granules per platelet (N=3 mice per genotype; 
Student’s t-test with Welch’s correction). C, Spreading of platelets on fibrinogen. 
Platelets were stained with -tubulin (red) and Phalloidin (green). Scale bars, 10 m. 
(insets: 2 m). Images are representative of 6 independent experiments. D, Representative 
images of activated thrombin platelets spread on fibrinogen for 30 min, in presence of 
vehicle (DMSO 0.01%) or the phosphatase inhibitors Okadaic acid (OA, 250nM) or 
Fostriecin  (Fos, 5M). Platelets were stained as in C). Scale bars, 5 m.  E, 
Quantification of platelet morphology after thrombin activation on fibrinogen for 30 min. 
Representative images of discoid, filopodial, pseudopod, llamellipodia, abnormal 
llamellipodia and spread platelets are shown on the left. Scale bars, 5 m. The plot 
represents the percentage (mean ± SEM; Mann-Whitney test) of cells in each category 
(>150 cells per experiment from 3 independent experiments). In panels A,B,E  *, P<0.05; 






Figure 5. Phospho-proteomic analysis in Mastl-mutant platelets. A, Levels of phospho-
MAPK/CDK substrates (proline-directed phosphosites) in resting platelets (0 min) or 
platelets activated with 0.05 IU/mL of thrombin for 3, 7 and 15 min from the indicated 
genotypes. The image represents two separate experiments. B, Schematic representation 
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of the protocol used in phophoproteomics experiments. The plot represents the percentage 
of peptides phosphorylated in serine (pS), threonine (pT) or tyrosine (pY) over the total 
of phosphopeptides detected. A pool of platelets from three mice per genotype were used 
in each time point. C,D, Fold change (log2) of all identified phosphosites in 
Mastl(ED/ED) (C) or Mastl(∆/∆) (D) versus Mastl(+/+) platelets in resting conditions. 
The enrichment of specific KEGG pathways in hyperphosphorylated (log2FC  0.75) or 
hypophosphorylated (log2FC  0.75) sites was calculated using the mouse platelet 
proteome as background. See Supplementary Tables 2-3 for a complete list of enriched 
pathways. FDR=False discovery rate. E, Analysis of hyperphosphorylated motifs in 
Mastl(ED/ED) vs. Mastl(+/+) resting platelets (left) or 3 min after activation with 
thrombin (right) using the de novo motif finder tool from the Posttraslational Modification 





Figure 6. Activation of focal adhesion and actin dynamics pathways in Mastl-mutant 
platelets.  Immunoblot analysis of total protein extracts from platelets in resting (0 min) 
or thrombin-activated conditions (3, 7 and 15 min). When indicated, platelets were pre-
treated with phosphatase (Fostriecin) and kinase (Compound C, H89, Gö6983 which 
inhibit Ampk, Pka and Pkc, respectively) inhibitors for 15 min at 37ºC before activation. 
Pools of platelets from 3 mice per genotype were used in each condition. The image 
represents 3 separate experiments. Antibodies are referred to by their commercial name 





Figure 7. Platelet defects in Mastl(ED/ED) mutant mice are mimicked with actin 
polymerization inhibitors and rescued by inhibiting inside-out kinases. A, Representative 
images of wild-type platelets treated with cytochalasin D (CytD) or jasplakinolide 
(Jasplak) 15 min after activation with thrombin. Untreated wild-type or mutant platelets 
are shown as a control. B, Percentage of Annexin V-positive cells, as quantified by flow 
cytometry with specific antibodies, in platelets (as labelled with CD41-specific 
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antibodies) with the indicated genotypes in the absence or presence of cytochalasin D 
(CytD), jasplakinolide (Jasplak) or the Bcl2-family inhibitor ABT-263 (used as a control 
for the induction of cell death), one, three or six h after activation with thrombin. Bars 
represent mean ± SEM (Student’s t-test with Welch’s correction). C, Representative 
images of Mastl(ED/ED) platelets activated with 0.05 IU/mL of thrombin and spread on 
fibrinogen for 30 min, in presence of vehicle (DMSO 0.01%) or the kinase inhibitors 
Compound C (CompC 10 nM), H89 (10 nM) or Gö6983 (500 nM). In A and C, platelets 
were stained with -tubulin (red) and Phalloidin (green), and plots show the percentage 
(mean ± SEM) of cells in the categories described in Figure 4E (n>150 cells per 
experiment from 3 independent experiments). Scale bars, 5 m. In A-C, *, P<0.05; **, 





Figure 8. Functional defects in Mastl(ED/ED) mutant platelets are mimicked with 
phosphatase inhibitors and rescued by inhibiting inside-out kinases in vivo. A,B, Survival 
curves after pulmonary embolism in Mastl(+/+) mice treated with the phosphatase 
inhibitor Fostriecin (A), or Mastl(ED/ED) mice treated with kinase inhibitors (B) for 1 h 
before of the induction of pulmonary embolism. The number of mice per group is 
indicated in the plot. NT=non treated. ***, P<0.001 (Log-rank test with Bonferroni 
correction). Representative images of hematoxylin and eosin stained lungs are shown on 
the right (N=3 mice per genotype). C, Time to death of the experimental groups in panels 
52 
 
A and B. Bars represent mean ± SEM. *, P<0.05; **, P<0.01; ***, P<0.001 (Student’s t-
test with Welch’s correction). 
   
